THORATEC CORP Form 8-K July 29, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 29, 2004
THORATEC CORPORATION

,	t as specified in its charter) fornia	
(State of Other Jurisa	liction of Incorporation)	
1-8145	94-2340464	
(Commission File Number)	(IRS Employer Identification Number)	
	eridge Drive California 94588	
	tive offices including zip code) 347-8600	
, ,	number, including area code) oplicable	
(Former name or former addr	ess, if changed since last report)	

TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition

Signature EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 12. Results of Operations and Financial Condition

On July 29, 2004, Thoratec Corporation (the Company) issued a press release announcing its fiscal 2004 second quarter results, the text of which is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including the exhibit, is furnished pursuant to Item 12 and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in the Current Report on Form 8-K, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

No.	Exhibit	
99.1	Press Release, dated July 29, 2004, regarding fiscal 2004 second quarter results.	
	2	

Table of Contents

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated as of July 29, 2004

THORATEC CORPORATION

By: /s/ M. Wayne Boylston

M. Wayne Boylston Senior Vice President, Chief Financial Officer and Secretary

3

Table of Contents

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued by Thoratec Corporation, dated July 29, 2004.

4